SFMBT2超甲基化促进结直肠癌癌症进展，是晚期CRC的潜在非侵入性生物标志物
SFMBT2 hypermethylation promotes colorectal cancer progression and is a potential noninvasive biomarker for advanced CRC.
摘要(中文译文)
SFMBT2蛋白是一种参与转录调控和癌症生物学的多梳族蛋白。在此，我们研究了启动子高甲基化在结直肠癌（CRC）发生发展中的作用及其临床意义。利用CRC细胞系、FFPE组织、血浆样本和公共数据集，我们发现启动子高甲基化与SFMBT2的转录沉默相关。SFMBT2在正常肠黏膜中表达较高，但在进展期腺瘤、原发性CRC和转移性病灶中逐渐降低，并伴有启动子甲基化水平升高。血浆SFMBT2甲基化水平升高与III期CRC较高的复发风险及IV期疾病的不良预后相关。生物信息学分析进一步将SFMBT2高表达与免疫细胞浸润增强及免疫相关通路的激活联系起来。这些发现表明，SFMBT2高甲基化可作为晚期CRC复发风险分层和预后评估的潜在无创生物标志物，并提示SFMBT2在塑造肿瘤免疫微环境中发挥作用。
Abstract
The SFMBT2 protein is a Polycomb group protein implicated in transcriptional regulation and cancer biology. Here, we investigated the role of promoter hypermethylation in colorectal cancer (CRC) development and its clinical relevance. Using CRC cell lines, FFPE tissues, plasma samples, and public datasets, we show that promoter hypermethylation is associated with the transcriptional silencing of . expression was high in normal intestinal mucosa but progressively reduced in advanced adenoma, primary CRC, and metastatic lesions, accompanied by increased promoter methylation. Elevated plasma methylation was associated with higher recurrence risk in stage III CRC and poor prognosis in stage IV disease. Bioinformatic analyses further linked high expression to enhanced immune cell infiltration and activation of immune-related pathways. These findings identify hypermethylation as a potential noninvasive biomarker for recurrence risk stratification and prognostic assessment in advanced CRC, and suggest a role for in shaping the tumor immune microenvironment.
如何引用
AMA
Wei Wang, Ling Yu, Wenyuan He, Jingyi Wu, Yuansen Li, Wenzhi Cui, et al. SFMBT2 hypermethylation promotes colorectal cancer progression and is a potential noninvasive biomarker for advanced CRC.. iScience. 2026; doi:10.1016/j.isci.2026.115019.
APA
Wei Wang, Ling Yu, Wenyuan He, Jingyi Wu, Yuansen Li, Wenzhi Cui, et al (2026). SFMBT2 hypermethylation promotes colorectal cancer progression and is a potential noninvasive biomarker for advanced CRC.. iScience. https://doi.org/10.1016/j.isci.2026.115019
GB/T 7714
Wei Wang, Ling Yu, Wenyuan He, Jingyi Wu, Yuansen Li, Wenzhi Cui, et al. SFMBT2 hypermethylation promotes colorectal cancer progression and is a potential noninvasive biomarker for advanced CRC.[J]. iScience, 2026 doi:10.1016/j.isci.2026.115019.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出